← Browse by Condition
Medical Condition

follicular lymphoma fl

Total Trials
5
Recruiting Now
5
Trial Phases
Phase 1, Phase 1, Phase 2

Lymphoma trials span diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, mantle cell lymphoma, and T-cell lymphomas β€” each with distinct biology and treatment response. CAR-T cell therapy has established a new standard in relapsed/refractory DLBCL, and trials now aim to move this approach earlier in the treatment sequence.

Active trials evaluate bispecific antibodies (mosunetuzumab, epcoritamab, glofitamab), next-generation CAR-T cell products (CD19/CD22 dual targets, BCMA-targeting), BTK inhibitors in B-cell lymphomas, and total metabolic volume on PET as a predictive biomarker for treatment adaptation.

Frequently Asked Questions — follicular lymphoma fl Clinical Trials

How many clinical trials are currently recruiting for follicular lymphoma fl?
ClinicalMetric currently tracks 5 actively recruiting clinical trials for follicular lymphoma fl, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 5. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for follicular lymphoma fl?
follicular lymphoma fl research spans Phase 1 (3 trials), Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a follicular lymphoma fl clinical trial?
Eligibility criteria for follicular lymphoma fl trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
3
Phase 2
1
Top Sponsors
Nurix Therapeutics, Inc. 2 trials
iOMEDICO AG 1 trial
Hospices Civils de Lyon 1 trial
ModeX Therapeutics, An OPKO Health Company 1 trial

Recruiting Clinical Trials

NCT04830137 Phase 1
Recruiting
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Enrollment
248 pts
Location
United States
Sponsor
Nurix Therapeutics, Inc.
View Trial →
NCT06043011
Recruiting
Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Enrollment
2,950 pts
Location
Germany
Sponsor
iOMEDICO AG
View Trial →
NCT03869619
Recruiting
REal World Data in LYmphoma and Survival in Adults
Enrollment
6,000 pts
Location
France
Sponsor
Hospices Civils de Lyon
View Trial →
NCT05131022 Phase 1
Recruiting
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Enrollment
572 pts
Location
United States, Franc...
Sponsor
Nurix Therapeutics, Inc.
View Trial →
NCT07249905 Phase 1, Phase 2
Recruiting
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
Enrollment
180 pts
Location
Australia
Sponsor
ModeX Therapeutics, An OPKO He...
View Trial →

Related Conditions

mantle cell lymphoma mcl (4) marginal zone lymphoma mzl (4) chronic lymphocytic leukemia cll (3) diffuse large b cell lymphoma dlbcl (3) small lymphocytic lymphoma sll (2) waldenstrom macroglobulinemia wm (2) primary central nervous system lymphoma pcnsl (2) waldenstr m s macroglobulinemia wm (1) diffuse large b lymphoma dlbcl (1) t cell lymphoma t nhl (1) hodgkin s lymphoma hl (1) burkitt lymphoma bl (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology